{
    "info": {
        "nct_id": "NCT03434418",
        "official_title": "A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations",
        "inclusion_criteria": "* EGFR mutations as performed on a CLIA certified laboratory demonstrating EGFR exon 18 G719X, exon 20 S768I, or exon 21 L861Q. Patients with compound (also referred to as multiple mutations) will be eligible provided the NSCLC demonstrates one of these mutations).\n* Histological or cytological confirmation diagnosis of Stage 4 NSCLC.\n* Measurable disease by RECIST 1.1 (please refer to appendix 4)\n* The following laboratory values obtained ≤ 14 days prior to study initiation.\n* Hematology: ANC ≥ 1, 500 / ml, platelet count, ≥ 100,000 / ml, hemoglobin ≥ 9.0 g / dl\n* Hepatic:ALT or ALT < 2.5 times ULN if no demonstrable liver metastases or <5 times ULN in the presence of liver metastases\n* Total bilirubin < 1.5 times ULN if no liver metastases or < 3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases\n* Renal: Cockcroft-Gault calculated creatinine clearance of ≥ 45 ml/min or creatinine ≤1.5 x ULN\n* Have normal QT interval on ECG evaluation QT corrected of ≤ 450 ms in males or ≤ 470 ms in females obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine-derived QTc value\n* Cardiac ejection fraction of ≥ 45%\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1\n* Negative pregnancy test done ≤7 days (or per institutional policy) prior to treatment, for women of childbearing potential only. Female must use highly effective contraceptive measures, and must have a negative pregnancy test or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n* Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n* Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n* Male subjects must be willing to use barrier contraception\n* Age ≥ 18 years\n* Provision of written informed consent prior to any study-specific procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior therapy with EGFR TKI therapy\n* Greater than 2 lines of prior systemic therapy for metastatic non-small cell lung cancer.\n* Any cytotoxic chemotherapy or other anticancer drugs from previous treatment regimen or clinical study within 14 days of first dose of study drug.\n* Treatment with an investigational drug within 5 half-lives of the compound\n* Other active malignancy ≤ 2 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment (i.e. hormonal therapy) for their cancer\n* Prior radiotherapy ≤ 14 days\n* Untreated symptomatic brain metastases (treated brain metastases are allowed provided > 14 days have elapsed from completion of radiotherapy and patient is neurologically stable as assessed by treating physician).\n* Malabsorption syndrome, refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib\n* Detection of concurrent EGFR mutation with exon 20 T790M, exon 19 deletion, exon 21 L858R mutation or exon 20 insertion. Patients with compound (also referred to as multiple mutations) will be excluded if the molecular testing includes one of these mutations.\n* Active pregnancy or breast-feeding: Pregnant women are excluded from this study because the effects of osimertinib on the development of the fetus are unknown, and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib, breastfeeding should be discontinued if the mother is treated with these agents.\n* Grade ≥ 2 blurred vision, conjunctivitis, corneal ulcer, dry eye, or keratitis",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Have normal QT interval on ECG evaluation QT corrected of ≤ 450 ms in males or ≤ 470 ms in females obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine-derived QTc value",
            "criterions": [
                {
                    "exact_snippets": "Have normal QT interval on ECG evaluation QT corrected of ≤ 450 ms in males or ≤ 470 ms in females",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "value in males",
                            "expected_value": {
                                "operator": "<=",
                                "value": 450,
                                "unit": "ms"
                            }
                        },
                        {
                            "requirement_type": "value in females",
                            "expected_value": {
                                "operator": "<=",
                                "value": 470,
                                "unit": "ms"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine-derived QTc value",
                    "criterion": "QTc interval measurement method",
                    "requirements": [
                        {
                            "requirement_type": "number of ECGs",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "ECGs"
                            }
                        },
                        {
                            "requirement_type": "measurement source",
                            "expected_value": "screening clinic ECG machine-derived QTc value"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation",
            "criterions": [
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization by hysterectomy",
                    "criterion": "irreversible surgical sterilization by hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization by ... bilateral oophorectomy",
                    "criterion": "irreversible surgical sterilization by bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilization by ... bilateral salpingectomy",
                    "criterion": "irreversible surgical sterilization by bilateral salpingectomy",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "but not tubal ligation",
                    "criterion": "tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.",
            "criterions": [
                {
                    "exact_snippets": "aged more than 50 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrheic for at least 12 months",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "following cessation of all exogenous hormonal treatments",
                    "criterion": "exogenous hormonal treatment",
                    "requirements": [
                        {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histological or cytological confirmation diagnosis of Stage 4 NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "Histological or cytological confirmation diagnosis",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage 4 NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "4"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease by RECIST 1.1 (please refer to appendix 4)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by RECIST 1.1",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution",
            "criterions": [
                {
                    "exact_snippets": "Women under 50 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrheic for 12 months or more",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "following cessation of exogenous hormonal treatments",
                    "criterion": "cessation of exogenous hormonal treatments",
                    "requirements": [
                        {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "LH and FSH levels in the post-menopausal range for the institution",
                    "criterion": "LH and FSH levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "post-menopausal range for the institution"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The following laboratory values obtained ≤ 14 days prior to study initiation.",
            "criterions": [
                {
                    "exact_snippets": "laboratory values obtained ≤ 14 days prior to study initiation",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "collection_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to study initiation"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac ejection fraction of ≥ 45%",
            "criterions": [
                {
                    "exact_snippets": "Cardiac ejection fraction of ≥ 45%",
                    "criterion": "cardiac ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test done ≤7 days (or per institutional policy) prior to treatment, for women of childbearing potential only. Female must use highly effective contraceptive measures, and must have a negative pregnancy test or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test done ≤7 days (or per institutional policy) prior to treatment, for women of childbearing potential only",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "Female must use highly effective contraceptive measures",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening",
                    "criterion": "child-bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "evidence of non-child-bearing potential",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatic:ALT or ALT < 2.5 times ULN if no demonstrable liver metastases or <5 times ULN in the presence of liver metastases",
            "criterions": [
                {
                    "exact_snippets": "ALT or ALT < 2.5 times ULN if no demonstrable liver metastases",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "no demonstrable liver metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT or ALT ... <5 times ULN in the presence of liver metastases",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "presence of liver metastases"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provision of written informed consent prior to any study-specific procedures",
            "criterions": [
                {
                    "exact_snippets": "Provision of written informed consent",
                    "criterion": "written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to any study-specific procedures",
                    "criterion": "timing of informed consent",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study-specific procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EGFR mutations as performed on a CLIA certified laboratory demonstrating EGFR exon 18 G719X, exon 20 S768I, or exon 21 L861Q. Patients with compound (also referred to as multiple mutations) will be eligible provided the NSCLC demonstrates one of these mutations).",
            "criterions": [
                {
                    "exact_snippets": "EGFR mutations as performed on a CLIA certified laboratory demonstrating EGFR exon 18 G719X, exon 20 S768I, or exon 21 L861Q",
                    "criterion": "EGFR mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation_presence",
                            "expected_value": [
                                "EGFR exon 18 G719X",
                                "EGFR exon 20 S768I",
                                "EGFR exon 21 L861Q"
                            ]
                        },
                        {
                            "requirement_type": "testing_method",
                            "expected_value": "CLIA certified laboratory"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with compound (also referred to as multiple mutations) will be eligible provided the NSCLC demonstrates one of these mutations",
                    "criterion": "compound EGFR mutations",
                    "requirements": [
                        {
                            "requirement_type": "eligibility_with_compound_mutations",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NSCLC_demonstrates_mutation",
                            "expected_value": [
                                "EGFR exon 18 G719X",
                                "EGFR exon 20 S768I",
                                "EGFR exon 21 L861Q"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male subjects must be willing to use barrier contraception",
            "criterions": [
                {
                    "exact_snippets": "Male subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "must be willing to use barrier contraception",
                    "criterion": "use of barrier contraception",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal: Cockcroft-Gault calculated creatinine clearance of ≥ 45 ml/min or creatinine ≤1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Cockcroft-Gault calculated creatinine clearance of ≥ 45 ml/min",
                    "criterion": "creatinine clearance (Cockcroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine ≤1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematology: ANC ≥ 1, 500 / ml, platelet count, ≥ 100,000 / ml, hemoglobin ≥ 9.0 g / dl",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 1, 500 / ml",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/ ml"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet count, ≥ 100,000 / ml",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ ml"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin ≥ 9.0 g / dl",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g / dl"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior therapy with EGFR TKI therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy with EGFR TKI therapy",
                    "criterion": "prior EGFR TKI therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior radiotherapy ≤ 14 days",
            "criterions": [
                {
                    "exact_snippets": "Prior radiotherapy ≤ 14 days",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since prior radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Detection of concurrent EGFR mutation with exon 20 T790M, exon 19 deletion, exon 21 L858R mutation or exon 20 insertion. Patients with compound (also referred to as multiple mutations) will be excluded if the molecular testing includes one of these mutations.",
            "criterions": [
                {
                    "exact_snippets": "Detection of concurrent EGFR mutation with exon 20 T790M, exon 19 deletion, exon 21 L858R mutation or exon 20 insertion.",
                    "criterion": "EGFR mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "mutation_type",
                            "expected_value": [
                                "exon 20 T790M",
                                "exon 19 deletion",
                                "exon 21 L858R mutation",
                                "exon 20 insertion"
                            ]
                        },
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with compound (also referred to as multiple mutations) will be excluded if the molecular testing includes one of these mutations.",
                    "criterion": "compound EGFR mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "mutation_type",
                            "expected_value": [
                                "exon 20 T790M",
                                "exon 19 deletion",
                                "exon 21 L858R mutation",
                                "exon 20 insertion"
                            ]
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with an investigational drug within 5 half-lives of the compound",
            "criterions": [
                {
                    "exact_snippets": "Treatment with an investigational drug within 5 half-lives of the compound",
                    "criterion": "treatment with an investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "half-lives of the compound"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grade ≥ 2 blurred vision, conjunctivitis, corneal ulcer, dry eye, or keratitis",
            "criterions": [
                {
                    "exact_snippets": "Grade ≥ 2 blurred vision",
                    "criterion": "blurred vision",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥ 2 ... conjunctivitis",
                    "criterion": "conjunctivitis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥ 2 ... corneal ulcer",
                    "criterion": "corneal ulcer",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥ 2 ... dry eye",
                    "criterion": "dry eye",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade ≥ 2 ... keratitis",
                    "criterion": "keratitis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated symptomatic brain metastases (treated brain metastases are allowed provided > 14 days have elapsed from completion of radiotherapy and patient is neurologically stable as assessed by treating physician).",
            "criterions": [
                {
                    "exact_snippets": "Untreated symptomatic brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "not untreated and symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "treated brain metastases are allowed provided > 14 days have elapsed from completion of radiotherapy",
                    "criterion": "treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "time since completion of radiotherapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patient is neurologically stable as assessed by treating physician",
                    "criterion": "neurological stability",
                    "requirements": [
                        {
                            "requirement_type": "neurological stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Greater than 2 lines of prior systemic therapy for metastatic non-small cell lung cancer.",
            "criterions": [
                {
                    "exact_snippets": "Greater than 2 lines of prior systemic therapy for metastatic non-small cell lung cancer.",
                    "criterion": "prior systemic therapy lines for metastatic non-small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any cytotoxic chemotherapy or other anticancer drugs from previous treatment regimen or clinical study within 14 days of first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Any cytotoxic chemotherapy or other anticancer drugs from previous treatment regimen or clinical study within 14 days of first dose of study drug.",
                    "criterion": "prior cytotoxic chemotherapy or other anticancer drugs",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malabsorption syndrome, refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib",
            "criterions": [
                {
                    "exact_snippets": "Malabsorption syndrome ... that would preclude adequate absorption of osimertinib",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory nausea and vomiting ... that would preclude adequate absorption of osimertinib",
                    "criterion": "refractory nausea and vomiting",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic gastrointestinal diseases ... that would preclude adequate absorption of osimertinib",
                    "criterion": "chronic gastrointestinal diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to swallow the formulated product ... that would preclude adequate absorption of osimertinib",
                    "criterion": "inability to swallow the formulated product",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous significant bowel resection that would preclude adequate absorption of osimertinib",
                    "criterion": "previous significant bowel resection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on absorption of osimertinib",
                            "expected_value": "precludes adequate absorption"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active pregnancy or breast-feeding: Pregnant women are excluded from this study because the effects of osimertinib on the development of the fetus are unknown, and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib, breastfeeding should be discontinued if the mother is treated with these agents.",
            "criterions": [
                {
                    "exact_snippets": "Active pregnancy ... Pregnant women are excluded from this study",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding ... breastfeeding should be discontinued if the mother is treated with these agents",
                    "criterion": "breast-feeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other active malignancy ≤ 2 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment (i.e. hormonal therapy) for their cancer",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy ≤ 2 years prior to registration",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix",
                    "criterion": "type of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "Non-melanotic skin cancer",
                                "carcinoma-in-situ of the cervix"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If there is a history of prior malignancy, patients must not be receiving other specific treatment (i.e. hormonal therapy) for their cancer",
                    "criterion": "treatment for prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Total bilirubin < 1.5 times ULN if no liver metastases or < 3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin < 1.5 times ULN if no liver metastases",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "liver metastases",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Total bilirubin < 3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "Gilbert's Syndrome or liver metastases",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}